SFX by Ex Libris Inc.

Title:	The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins
Source:	Science [0036-8075] Lu, G yr:2013

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Krönke, J. "Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells." Science 343.6168 (2013): 301-305.
description	2.	Ito, T. "Identification of a primary target of thalidomide teratogenicity." Science 327.5971 (2010): 1345-1350.
description	3.	Filippakopoulos, P. "Selective inhibition of BET bromodomains." Nature 468.7327 (2010): 1067-1073.
description	4.	Wei, W. "Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex." Nature 428.6979 (2004): 194-8.
description	5.	Zeldis, Jerome B. "A review of the history, properties, and use of the immunomodulatory compound lenalidomide." Annals of the New York Academy of Sciences 1222.1 (2011): 76-82.
description	6.	Krönke, J. "Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS." Nature 523.7559 (2015): 183-8.
description	7.	Ito, T. "Deciphering the mystery of thalidomide teratogenicity." Congenital anomalies 52.1 (2012): 1-7.
description	8.	Adamson, B. "A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response." Nature Cell Biology 14.3 (2012): 318-328.
description	9.	Ebert, B. "Mutations in RNA splicing machinery in human cancers." The New England journal of medicine 365.26 (2011): 2534-2535.
description	10.	Singhal, S. "Antitumor activity of thalidomide in refractory multiple myeloma." New England Journal of Medicine, The 341.21 (1999): 1565-1571.
description	11.	Delmore, Jake E. "BET Bromodomain Inhibition as a Therapeutic Strategy to Target c - Myc." Cell 146.6 (2011): 2011-917.
description	12.	Therapontos, C. "Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation." Proceedings of the National Academy of Sciences of the United States of America 106.21 (2009): 8573-8.
description	13.	Joazeiro, C. "RING Domain E3 Ubiquitin Ligases." Annual Review of Biochemistry 78.1 (2009): 399-434.
description	14.	Yabu, T. "Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate." Blood 106.1 (2005): 125-134.
description	15.	Tseng, S.. "Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses." Journal of the American Academy of Dermatology 35.6 (1996): 969-979.
description	16.	Bradley, Anthony R. "The SGC beyond structural genomics: redefining the role of 3D structures by coupling genomic stratification with fragment-based discovery." Essays Biochem 61.5 (2017): 495-503.
description	17.	Zuber, J. "RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia." Nature 478.7370 (2011): 524-528.
description	18.	Chung, C. "Discovery and characterization of small molecule inhibitors of the BET family bromodomains." Journal of medicinal chemistry 54.11 (2011): 3827-3838.
description	19.	Nicodeme, E. "Suppression of inflammation by a synthetic histone mimic." Nature 468.7327 (2010): 1119-1123.
description	20.	WEI, W. "The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase." Cancer cell 8.1 (2005): 25-33.